MedTrace Logo

Distinction Risk of Severe Infection in Febrile Neutropenia After Chemotherapy

NCT03434795 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1900

Last updated 2026-04-22

No results posted yet for this study

Summary

Evaluate the reproducibility and validate a posteriori a new rule of clinical decision on a multi-center population of children with a post-chemotherapy febrile neutropenia

Conditions

  • Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy

Sponsors & Collaborators

  • Ministry of Health, France

    collaborator OTHER_GOV

  • Ligue contre le cancer, France

    collaborator OTHER

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • François Dubos, MD, PhD · University Hospital, Lille

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03434795 on ClinicalTrials.gov